Anticancer agent 330 

Anticancer agent 330 is a semi-synthetic derivative of Salinomycin (HY-15597) conjugated with triphenylphosphine, as well as an anticancer agent. Anticancer agent 330 induces G₀/G₁ phase cell cycle arrest. Anticancer agent 330 reduces the production of ROS in cells. Anticancer agent 330 impairs mitochondrial integrity. Anticancer agent 330 promotes Autophagy. Anticancer agent 330 can be used in research related to ovarian cancer^[1].

Anticancer agent 330 (Compound 8) (72 h) exhibits cytotoxic activity comparable to that of Salinomycin (HY-15597) in the A2780, Caov3, OVCAR3, SKOV3 ovarian cancer cell lines and MRC-5 pd19 fibroblasts, and shows improved selectivity towards A2780 and OVCAR3 cells compared with Salinomycin^[1].
Combination treatment with anticancer agent 330 (IC₅₀ doses; 72 h) and Carboplatin (HY-17393) produces nearly additive interactions in A2780, OVCAR3 and SKOV3 ovarian cancer cell lines, induces moderate antagonistic effects in Caov3 ovarian cancer cells, and exerts differential impacts on cell viability across different cell lines^[1].
Anticancer agent 330 (IC₅₀ doses; 72 h) regulates the expression of apoptosis- and cell cycle-related proteins in a cell line-dependent manner in A2780, Caov3, OVCAR3 and SKOV3 ovarian cancer cell lines, and its effects when used alone or in combination with Carboplatin are similar to those of Salinomycin^[1].
Anticancer agent 330 regulates ROS production and disrupts mitochondrial membrane potential in a cell line-dependent manner, and this effect involves the A2780, Caov3, OVCAR3 and SKOV3 ovarian cancer cell lines; its efficacy when used alone or in combination with Carboplatin is similar to that of Salinomycin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1157.26

C₆₃H₈₇BrN₃O₁₀P

3127025-65-1

[H][C@]1(O[C@H](CC[C@@H]1C)[C@H](C(O)=O)CC)[C@H]([C@@H]([C@@H](C([C@@H]([C@H]2O[C@@]3([C@@H](C[C@@H]2C)C)C=CC([C@@]4(O3)CC[C@@]([C@H]5CC[C@](CC)([C@@H](O5)C)O)(O4)C)N6C=C(N=N6)C[P+](C7=CC=CC=C7)(C8=CC=CC=C8)C9=CC=CC=C9)CC)=O)C)O)C.[Br-]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Michalak M, et al. A combination of salinomycin or its C20 triphenylphosphonium-conjugated derivative with carboplatin leads to autophagy in ovarian cancer cells - An in vitro study. European journal of medicinal chemistry. 2026 Apr 05;307:118656.